Floatz logo

TAK228

CD30+ Peripheral T-cell Lymphoma

M.D. Anderson Cancer CenterPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
89/ 100

Competitive context

36 Active assets in the CD30+ Peripheral T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 2BB
ETOPOSIDE
Alliance for Clinical Trials in Oncology
Phase 4BB
DEXAMETHASONE
Zhengzhou University
Phase 4BB
PREDNISONE TABLETS
City of Hope Medical Center
Phase 2BB
FILGRASTIM
City of Hope Medical Center
Phase 2BB

View all 50 →

Same molecule, other indications

TAK228 is also rated in:

ovarian neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian carcinosarcomaDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian serous adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →